CELU Celularity Corp: רווח נקי למניה ב-12 החודשים האחרונים

Celularity Inc. (CELU) faces challenges regarding high capital expenditures and uncertainty surrounding the certification of new cell therapy methodologies. Meanwhile, Celularity Inc. (CELU) relies on patented placental tissue cultivation methods, which secure its status as a leader in regenerative medicine. This chart captures the EPS at 46.90, while the business implements automated bioreactors to eliminate human error.

To filter for high-quality assets, an investor must evaluate real yield dynamics stripped of one-time accounting adjustments. This metric measures the annual growth rate of net income per share, which allows for an assessment of the resilience of Celularity Inc. (CELU) to biomaterial supply chain disruptions and geopolitical delays in clinical trials by analyzing the net income per share YoY ttm chart.